Avadel Pharmaceuticals plc (NASDAQ: AVDL) started the day on Wednesday, with a price increase of 1.37% at $8.16, before settling in for the price of $8.05 at the close. Taking a more long-term approach, AVDL posted a 52-week range of $7.39-$19.09.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been -40.57% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 4.78%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 75.00%. This publicly-traded company’s shares outstanding now amounts to $96.34 million, simultaneously with a float of $88.15 million. The organization now has a market capitalization sitting at $786.30 million. At the time of writing, stock’s 50-day Moving Average stood at $11.20, while the 200-day Moving Average is $14.33.
Avadel Pharmaceuticals plc (AVDL) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Drug Manufacturers – Specialty & Generic Industry. Avadel Pharmaceuticals plc’s current insider ownership accounts for 8.52%, in contrast to 74.86% institutional ownership. According to the most recent insider trade that took place on Jan 13 ’25, this organization’s Director bought 10,000 shares at the rate of 8.04, making the entire transaction reach 80,450 in total value, affecting insider ownership by 104,055. Preceding that transaction, on Jan 13 ’25, Company’s Director bought 30,000 for 7.84, making the whole transaction’s value amount to 235,218. This particular insider is now the holder of 208,900 in total.
Avadel Pharmaceuticals plc (AVDL) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
Avadel Pharmaceuticals plc’s EPS increase for this current 12-month fiscal period is 75.00% and is forecasted to reach 0.15 in the upcoming year.
Avadel Pharmaceuticals plc (NASDAQ: AVDL) Trading Performance Indicators
Let’s observe the current performance indicators for Avadel Pharmaceuticals plc (AVDL). It’s Quick Ratio in the last reported quarter now stands at 2.60. The Stock has managed to achieve an average true range (ATR) of 0.71. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5.69.
In the same vein, AVDL’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.77, a figure that is expected to reach -0.04 in the next quarter, and analysts are predicting that it will be 0.15 at the market close of one year from today.
Technical Analysis of Avadel Pharmaceuticals plc (AVDL)
If we take a close look at the recent performances of Avadel Pharmaceuticals plc (NASDAQ: AVDL), its last 5-days Average volume was 3.32 million that shows progress from its year to date volume of 2.36 million. During the previous 9 days, stock’s Stochastic %D was recorded 15.01% While, its Average True Range was 0.75.
Raw Stochastic average of Avadel Pharmaceuticals plc (AVDL) in the period of the previous 100 days is set at 8.31%, which indicates a major fall in contrast to 18.64% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 130.02% that was higher than 79.91% volatility it exhibited in the past 100-days period.
